Drug intelligence / Profile preview

QL-112

Development stage: Unknown
Lead developer: Shenzhen Qinglan Biotechnology
Modality: Peptides
Administration: Transdermal

Overview

QL-112 is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist peptide developed by BioQingLam. It is formulated as a transdermal soluble microneedle patch, utilizing the company's proprietary delivery technology platform. The drug is currently in Phase III clinical development for the treatment of Type 2 Diabetes Mellitus (T2DM) and obesity. By targeting both GLP-1 and GIP receptors, QL-112 aims to improve glycemic control and promote weight loss through a needle-free, non-invasive administration route, potentially offering an alternative to traditional subcutaneous injections.

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on QL-112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QL-112.

Explore the full profile